Abstract: The present disclosure provides a pharmaceutical composition for preventing or treating cancer comprising a NUPR1 isoform A inhibitor as an active ingredient, a composition for diagnosing or predicting prognosis of cancer comprising an agent for measuring an expression or activity level of a NUPR1 isoform A, a kit for diagnosing or predicting prognosis of cancer comprising the composition, a method for screening a substance for inhibiting cancer cell proliferation or metastasis, a method for providing information for cancer cell proliferation or metastasis, a food composition for preventing or improving cancer comprising a NUPR1 isoform A inhibitor as an active ingredient, and a feed composition for preventing or improving cancer comprising a NUPR1 isoform A inhibitor as an active ingredient.

Abstract: A static magnetic field generator for treatment of cancer according to an embodiment of the present disclosure includes a static magnetic field generating unit, and a space in which a static magnetic field is formed by the static magnetic field generating unit, wherein the formed static magnetic field has a magnitude range of 0.1 mT to 4 T.

Abstract: The technology disclosed in the present specification relates to a nanoparticle providing medium for hyperthemia, and the nanoparticle providing medium for hyperthemia according to an embodiment may be formed so as to capture nanoparticles in a region or one or more divided regions and block contact between the nanoparticles and a body.

Abstract: The technology disclosed in the present specification is characterized in that it provides an apparatus and system for generating an alternating magnetic field for disease treatment that are significantly safer and have fewer side effects compared to conventional methods of treating tumors by using magnetic nanoparticles. The apparatus for generating the alternating magnetic field may further include a ferrite core at the outside the coil, through which a more uniform and dense alternating magnetic field may be applied. The technology disclosed in the present specification is characterized by providing an AC magnetic field generating device and system for disease treatment that is significantly safer and has fewer side effects compared to the conventional method of treating tumors using magnetic nanoparticles.

Abstract: Provided is a method of diagnosing a brain tumor by analyzing the increase or decrease in content of specific bacteria-derived extracellular vesicles by performing bacterial metagenomic analysis using a normal individual and a subject-derived sample, which makes it possible to diagnose and predict a risk group for a brain tumor early, to delay or prevent the onset of the disease through appropriate management, and even after the onset of a brain tumor, early diagnosis can be performed to reduce the incidence of the brain tumor, a therapeutic effect cannot be only increased, and the disease can be improved and recurrence thereof can be prevented by avoiding exposure to causative factors through metagenomic analysis in patients diagnosed with a brain tumor.

Abstract: Provided are an implantable medical device control system and a control method therefor, the system comprising: an implantable medical device implanted into the body so as to stimulate a specific area in the body; a management terminal for controlling the driving of the implantable medical device by communicating with the implantable medical device through a wireless communication method; and a management server connected with the management terminal so as to be capable of communicating therewith, assigning priority to each parameter included in patient condition information and storing and managing same, and providing the stored information, and thus, since priority is assigned to each parameter included in patient condition information and stimulation applied to a specific part in the body is adjusted according to the assigned priority, the entire parameter can be controlled such that a patient condition is maintained in a stabilized state by satisfying a preset reference value.

Abstract: Disclosed is a carbon material for a neurostimulation electrode. The carbon material is composed of a carbon fiber. The carbon fiber has a thickness of 1 to 1000 ?m, a linear density of 0.01 to 5.00 g/cm, and an aspect ratio of 100 to 1,000,000. Particularly, the carbon fiber material can be obtained by dry spinning carbon nanotubes, followed by liquid-based densification. The carbon material can be used in the fields of deep brain stimulation, spinal cord stimulation, etc. Also disclosed are an electrode assembly and a neurostimulation device, each including the carbon material.

Abstract: Disclosed is a carbon material for a neurostimulation electrode. The carbon material is composed of a carbon fiber. The carbon fiber has a thickness of 1 to 1000 ?m, a linear density of 0.01 to 5.00 g/cm, and an aspect ratio of 100 to 1,000,000. Particularly, the carbon fiber material can be obtained by dry spinning carbon nanotubes, followed by liquid-based densification. The carbon material can be used in the fields of deep brain stimulation, spinal cord stimulation, etc. Also disclosed are an electrode assembly and a neurostimulation device, each including the carbon material.

Abstract: The present invention relates to a method for diagnosing glioma by comparing the protein location of an individual to be diagnosed with the normal control nerve cells. More particularly, the present invention relates to a method for diagnosing glioma including determining that an individual has glioma when the expression level of GFR?4 in the endoplasmic reticulum is higher than that in the plasma membrane, and a method for screening a therapeutic agent for glioma. In the diagnostic method of the present invention, the protein expression levels in particular subcellular locations are compared, thereby accurately diagnosing glioma, diagnosing progression of glioma, and predicting prognosis after glioma surgery.

Abstract: The present invention relates to a composition for diagnosing a Parkinson's disease comprising mesenchymal stromal cells derived from adipose tissue, a method of providing information for diagnosing Parkinson's disease and/or the extent of the disease progression, a biomarker for diagnosing a Parkinson's disease, a method of screening a drug candidate treating Parkinson's disease where the drug candidate is a target of the biomarker, and an immortalized mesenchymal stromal cell from adipose tissue.

Abstract: The present invention relates to a composition for diagnosing a Parkinson's disease comprising mesenchymal stromal cells derived from adipose tissue, a method of providing information for diagnosing Parkinson's disease and/or the extent of the disease progression, a biomarker for diagnosing a Parkinson's disease, a method of screening a drug candidate treating Parkinson's disease where the drug candidate is a target of the biomarker, and an immortalized mesenchymal stromal cell from adipose tissue.

Abstract: The present invention relates to a method for diagnosing glioma by comparing the protein location of an individual to be diagnosed with the normal control nerve cells. More particularly, the present invention relates to a method for diagnosing glioma including determining that an individual has glioma when the expression level of GFR?4 in the endoplasmic reticulum is higher than that in the plasma membrane, and a method for screening a therapeutic agent for glioma. In the diagnostic method of the present invention, the protein expression levels in particular subcellular locations are compared, thereby accurately diagnosing glioma, diagnosing progression of glioma, and predicting prognosis after glioma surgery.

Abstract: A movement analysis device for rodents capable of variably adjusting a space where a rodent is placed in order to stimulate the behavior of the rodent so that motor functions of the rodent can be analyzed more effectively. The movement analysis device for rodents includes a body including a pair of side plates distanced from each other with a predetermined gap and a connector plate connecting one ends of the side plates together, the connector plate having a slit extending from one to the other one of the side plates; and an adjustment unit including an adjustment plate configured insertable between the side plates of the body and into the slit of the connector plate of the body and a support plate extending to a height reaching from a bottom to the slit to support the adjustment plate at one portion thereof. The support plate is semi-cylindrically shaped to form a cylindrical space together with the connector plate.

Abstract: The present invention relates to a method of determining the position of a deep brain stimulation (DBS) electrode which finds the position of the DBS electrode with respect to a deep brain target region, by using a first volume data set containing information on the deep brain target region and a second volume data set containing information on the DBS electrode implanted toward the deep brain target region, and which includes: a first step of generating a subvolume of the deep brain target region from the first volume data set, and also generating a subvolume of the DBS electrode from the second volume data set; and a second step of overlapping and displaying the subvolume of the deep brain target region and the subvolume of the DBS electrode.

Abstract: The present invention relates to a composition for diagnosing a Parkinson's disease comprising mesenchymal stromal cells derived from adipose tissue, a method of providing information for diagnosing Parkinson's disease and/or the extent of the disease progression, a biomarker for diagnosing a Parkinson's disease, and a method of screening a drug candidate treating Parkinson's disease where the drug candidate is a target of the biomarker.

Abstract: The present invention relates to a method of determining the position of a deep brain stimulation (DBS) electrode which finds the position of the DBS electrode with respect to a deep brain target region, by using a first volume data set containing information on the deep brain target region and a second volume data set containing information on the DBS electrode implanted toward the deep brain target region, and which includes: a first step of generating a subvolume of the deep brain target region from the first volume data set, and also generating a subvolume of the DBS electrode from the second volume data set; and a second step of overlapping and displaying the subvolume of the deep brain target region and the subvolume of the DBS electrode.

Abstract: A movement analysis device for rodents capable of variably adjusting a space where a rodent is placed in order to stimulate the behavior of the rodent so that motor functions of the rodent can be analyzed more effectively, The movement analysis device for rodents includes a body including a pair of side plates distanced from each other with a predetermined gap and a connector plate connecting one ends of the side plates together, the connector plate having a slit extending from one to the other one of the side plates; and an adjustment unit including an adjustment plate configured insertable between the side plates of the body and into the slit of the connector plate of the body and a support plate extending to a height reaching from a bottom to the slit to support the adjustment plate at one portion thereof. The support plate is semi-cylindrically shaped to form a cylindrical space together with the connector plate.